TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
11.35
+0.05 (0.44%)
Mar 24, 2026, 1:30 PM CST
TPEX:4157 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 145.09 | 74.14 | 374.66 | 243.11 | 364.93 |
Short-Term Investments | 674.82 | 751.28 | 598.2 | 591.11 | 495.38 |
Trading Asset Securities | 206.84 | 194.4 | 65.14 | 64.39 | 64.09 |
Cash & Short-Term Investments | 1,027 | 1,020 | 1,038 | 898.6 | 924.4 |
Cash Growth | 0.68% | -1.75% | 15.51% | -2.79% | 179.46% |
Accounts Receivable | 5.01 | 7.33 | 8.98 | 18.41 | 278.28 |
Other Receivables | 7.93 | 9.07 | 24.88 | 5.3 | 2.61 |
Receivables | 12.94 | 16.4 | 33.87 | 23.71 | 280.89 |
Inventory | 76.1 | 42.71 | 34.15 | 15.35 | 17.88 |
Other Current Assets | 4.15 | 7.16 | 4.37 | 11.57 | 8.84 |
Total Current Assets | 1,120 | 1,086 | 1,110 | 949.24 | 1,232 |
Property, Plant & Equipment | 17.31 | 67.47 | 90.61 | 56.6 | 80.43 |
Long-Term Investments | 3.41 | 2.45 | 9.71 | 23.98 | 53.9 |
Other Intangible Assets | 22.45 | 12.05 | 12.99 | 0.23 | 0.16 |
Other Long-Term Assets | 4.15 | 6.22 | 6.16 | 16.96 | 26.31 |
Total Assets | 1,167 | 1,174 | 1,230 | 1,047 | 1,393 |
Short-Term Debt | 35 | - | - | 3 | - |
Current Portion of Leases | 5.6 | 16.33 | 15.98 | 18.34 | 17.99 |
Current Income Taxes Payable | - | 0.11 | - | 3.07 | 27.86 |
Current Unearned Revenue | 0.15 | 0.15 | 0.15 | 0.15 | 0.18 |
Other Current Liabilities | 42.36 | 29.5 | 31.76 | 26.76 | 43.85 |
Total Current Liabilities | 83.11 | 46.08 | 47.89 | 51.32 | 89.88 |
Long-Term Leases | 8.62 | 42.39 | 58.71 | 17.13 | 35.47 |
Long-Term Unearned Revenue | 0.03 | 0.18 | 0.33 | 0.48 | 0.62 |
Pension & Post-Retirement Benefits | 0.63 | 3.31 | 4.01 | 8.05 | 13.15 |
Total Liabilities | 92.38 | 91.96 | 110.94 | 76.98 | 139.11 |
Common Stock | 20.77 | 20.94 | 20.94 | 20.91 | 20.91 |
Additional Paid-In Capital | 451.17 | 466.3 | 444.61 | 450.26 | 455.25 |
Retained Earnings | 634.32 | 640.6 | 678.68 | 542.05 | 778.3 |
Comprehensive Income & Other | -31.38 | -45.51 | -25.34 | -43.2 | -0.77 |
Shareholders' Equity | 1,075 | 1,082 | 1,119 | 970.03 | 1,254 |
Total Liabilities & Equity | 1,167 | 1,174 | 1,230 | 1,047 | 1,393 |
Total Debt | 49.22 | 58.71 | 74.69 | 38.47 | 53.46 |
Net Cash (Debt) | 977.54 | 961.11 | 963.3 | 860.13 | 870.94 |
Net Cash Growth | 1.71% | -0.23% | 12.00% | -1.24% | 177.67% |
Net Cash Per Share | 1.30 | 1.34 | 1.34 | 1.20 | 1.21 |
Filing Date Shares Outstanding | 860.06 | 717.84 | 717.84 | 716.84 | 716.84 |
Total Common Shares Outstanding | 860.06 | 717.84 | 717.84 | 716.84 | 716.84 |
Working Capital | 1,037 | 1,040 | 1,062 | 897.92 | 1,142 |
Book Value Per Share | 1.25 | 1.51 | 1.56 | 1.35 | 1.75 |
Tangible Book Value | 1,052 | 1,070 | 1,106 | 969.8 | 1,254 |
Tangible Book Value Per Share | 1.22 | 1.49 | 1.54 | 1.35 | 1.75 |
Machinery | - | 144.93 | 144.38 | 143.76 | 140.92 |
Leasehold Improvements | - | 60.79 | 60.66 | 60.71 | 60.67 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.